HC Wainwright Analysts Boost Earnings Estimates for RARE

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a note issued to investors on Tuesday, February 17th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings per share of ($1.55) for the quarter, up from their previous forecast of ($1.63). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q2 2026 earnings at ($1.20) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($4.05) EPS, Q1 2027 earnings at $0.28 EPS, Q2 2027 earnings at $1.19 EPS, Q3 2027 earnings at $1.55 EPS, Q4 2027 earnings at $2.64 EPS and FY2027 earnings at $5.66 EPS.

Several other equities analysts have also recently weighed in on the company. Wedbush reissued a “neutral” rating and set a $25.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday. Robert W. Baird cut their price target on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a report on Tuesday, December 30th. Leerink Partners reduced their price objective on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Barclays lowered their price objective on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, November 24th. Finally, Wells Fargo & Company cut their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday, December 30th. Sixteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $68.29.

Ultragenyx Pharmaceutical Price Performance

RARE stock opened at $22.72 on Thursday. Ultragenyx Pharmaceutical has a 52-week low of $18.41 and a 52-week high of $45.00. The company has a 50-day moving average of $25.40 and a two-hundred day moving average of $29.50. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -3.89 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The firm had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.Ultragenyx Pharmaceutical’s quarterly revenue was up 25.5% on a year-over-year basis. During the same period in the prior year, the company posted ($1.39) earnings per share.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 3,081 shares of the firm’s stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total value of $112,086.78. Following the completion of the transaction, the chief financial officer directly owned 95,146 shares of the company’s stock, valued at $3,461,411.48. This trade represents a 3.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 6,227 shares of company stock valued at $187,126 in the last three months. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently made changes to their positions in the business. Assetmark Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,024 shares in the last quarter. Huntington National Bank lifted its stake in Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares during the period. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical during the third quarter valued at approximately $39,000. Smartleaf Asset Management LLC boosted its holdings in Ultragenyx Pharmaceutical by 205.4% during the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares in the last quarter. Finally, Covestor Ltd grew its stake in shares of Ultragenyx Pharmaceutical by 26.0% in the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Analyst support and updated estimates: HC Wainwright reiterated a Buy and updated / raised multi‑quarter and FY‑2027 EPS forecasts, keeping a $50 target — a positive signal for future earnings trajectory and investor sentiment. HC Wainwright price target and estimates
• Positive Sentiment: Inducement RSU grants to new hires: Ultragenyx granted 22,917 restricted stock units to six newly hired non‑executive officers (vesting over four years) under its Employment Inducement Plan — indicates investment in talent for development/commercialization execution. Ultragenyx Reports Inducement Grant
• Neutral Sentiment: Mixed sell‑side views: Wedbush reiterated a Neutral rating while other outlets published a range of analyst price targets (median cited around $55) — keeps the stock in focus but provides no clear directional catalyst by itself. Wedbush reiterates Neutral
• Negative Sentiment: Ongoing securities‑class action notices and lead‑plaintiff deadlines: Multiple firms (Kessler Topaz, Schall, Faruqi, Pomerantz, Robbins Geller, Levi & Korsinsky, Rosen, etc.) are soliciting Ultragenyx investors in a suit covering Aug 3, 2023–Dec 26, 2025 with an April 6, 2026 lead‑plaintiff deadline — increases legal overhang and potential future liability. RARE Investor Alert: Kessler Topaz
• Negative Sentiment: Insider selling and institutional positioning: Recent filings highlighted insider sales (multiple officers) and mixed hedge fund moves (notable large reductions by some institutions) — potential signal of near‑term selling pressure or rebalancing. QuiverQuant summary (includes insider activity)
• Negative Sentiment: Pessimistic sell‑side note: Canaccord published a pessimistic forecast for RARE, adding downside analytical pressure amid mixed institutional flows and legal risk. Canaccord Genuity pessimistic forecast

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.